17th January 2025, Kathmandu
Om Megashree Pharmaceuticals Limited has officially received approval from the Securities Board of Nepal (SEBON) to issue an Initial Public Offering (IPO) of 1.8 million shares, valued at NPR 18 million.
Om Megashree Pharmaceuticals IPO Approved
The approval, granted on January 16, sets the stage for the company’s entry into the Nepalese capital market.
Details of the IPO
The company will issue shares worth NPR 180 million, a move that will increase its paid-up capital to NPR 600 million. The IPO marks a significant milestone for Om Megashree as it prepares to raise funds for expansion.
First Pharmaceutical Company in Nepal to Go Public
This IPO is a groundbreaking development, as Om Megashree Pharmaceuticals became the first pharmaceutical company in Nepal to enter the capital market. The move signifies a new era for the pharmaceutical sector, with opportunities for public investment in the industry.
Prabhu Capital to Manage the IPO
Om Megashree has appointed Prabhu Capital as the issue manager for the IPO. The company will oversee the distribution of shares to the public, ensuring a smooth and efficient process for investors.
Aiming for Growth and Expansion
The IPO aims to raise capital for further business expansion, allowing Om Megashree to enhance its products and services. This move will benefit both the company and Nepal’s pharmaceutical sector by improving product accessibility and public health outcomes.
Impact on Nepal’s Pharmaceutical Sector
The issuance of the IPO will create new opportunities for investors and provide necessary funding for Om Megashree’s growth. The pharmaceutical sector in Nepal is expected to benefit from increased public investment and improved industry transparency.
With the SEBON approval in place, Om Megashree Pharmaceuticals is ready to make history as the first pharmaceutical company in Nepal to go public. This significant step will open doors for the company and transform the landscape of the Nepalese pharmaceutical market.
For more: Om Megashree Pharmaceuticals IPO Approved